Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...
Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...
Bristol-Myers wins FDA nod for novel antipsychotic. DirecTV, Dish close in on merger to form largest US pay-TV service: ...